Beam Therapeutics to Present BEAM-301 Phase 1/2 Data at ESGCT Congress
The company said it will present initial data from its BEAM-301 Phase 1/2 trial in glycogen storage disease type Ia at the ESGCT 33rd Annual Congress.
The company said it will present initial data from its BEAM-301 Phase 1/2 trial in glycogen storage disease type Ia at the ESGCT 33rd Annual Congress.